Business Context and Reporting Period
This Form 8-K is filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on June 28, 2018, reporting events occurring on that date and an amendment filed on July 2, 2018. The filing details the results of the 2018 Annual Meeting of Stockholders and a subsequent amendment to the Company's Certificate of Incorporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Authorized Share Reduction: Stockholders approved an amendment to reduce the number of authorized common shares from 90,000,000 to 55,000,000. This amendment was filed with the state on July 2, 2018.
- Board Composition: Five director nominees were elected to serve until the 2019 annual meeting.
- Auditor Ratification: Stockholders ratified the selection of KMJ Corbin and Company, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, outlook, or specific risk factors. The primary focus is the successful execution of shareholder votes and the formal reduction of authorized equity.
Investor Verification Checklist
- Verify the effective date of the authorized share reduction (filed July 2, 2018) and its impact on future capital raising capacity.
- Confirm the identity of the newly elected directors and their tenure terms.
- Review the proxy statement referenced in the filing for detailed voting breakdowns and director biographies.
- Note the discrepancy between the metadata company name ("Harrow, Inc.") and the actual registrant ("Imprimis Pharmaceuticals, Inc.").